The utility of IMP3 immunohistochemical staining in differentiating nodular lymphocyte predominant Hodgkin Lymphoma from T-Cell/Histiocyte-Rich large B-Cell lymphoma

Abstract

Introduction Nodular lymphocyte predominant Hodgkin lymphoma (NLPHL) and T cell/histiocyte-rich large B-cell lymphoma (THRLBCL) have overlapping histological features that make their diagnosis challenging. Insulin-like growth factor II mRNA-binding protein 3 (IMP3) is a recently proposed diagnostic marker for Hodgkin’s lymphoma. The aim of this study was to determine the ability of IMP3 in differentiating NLPHL from THRLBCL. Methods In this retrospective study, the formalin-fixed paraffin-embedded blocks from 56 patients (28 NLPHL and 28 large B cell lymphoma (LBCL, including 16 THRLBCL and 12 DLBCL, NOS) cases based on immunohistochemistry (IHC) were included. Sample sections were stained for IMP3 using IHC method. Moderate to strong staining in at least 10% of tumor cells was considered positive IMP3 expression. Results The mean age of the patients was 41.25 ± 16.08 years old. The majority of the patients were male. There was a significant age difference between NLPHL (34.61 ± 16.44 years old) and LBCL (47.89 ± 12.85 years) groups (p = 0.001). No significant difference was seen in gender and site between NLPHL and LBCL groups. The expression of IMP3 was mainly strong in LBCL group, while it was heterogeneously distributed among NLPHL samples ranging from weak to strong (p < 0.001). It was determined that strong IMP3 expression at 55.00% can differentiate LBCL from NLPHL with 71.4% sensitivity and 71.4% specificity. Conclusion Our findings showed that IMP3 may be a good complement in differentiating NLPHL cases from THRLBCL.

IGF2BP3 as a Prognostic Biomarker in Well-Differentiated/Dedifferentiated Liposarcoma

“…DD LPS demonstrated higher cell positivity, p = 0.0054 (Figure S3A) and three DD LPS PDX models previously developed at our institution included in the tissue microarray maintained high IGF2BP3 positivity (Figure S3C). IGF2BP3 staining was homogenous and localized to the cytoplasm in positive samples, similar to previously validated cancers (Figure 3B) [22,38].…”

“…DD LPS demonstrated higher cell positivity, p = 0.0054 (Figure S3A) and three DD LPS PDX models previously developed at our institution included in the tissue microarray maintained high IGF2BP3 positivity (Figure S3C). IGF2BP3 staining was homogenous and localized to the cytoplasm in positive samples, similar to previously validated cancers (Figure 3B) [22,38]. To confirm the binding specificity of the IGF2BP3 antibody, and validate the prognostic value of IGF2BP3 in future studies, we performed Western blotting of a human liposarcoma cell line, LPS2, following CRISPR-cas9 mediated IGF2BP3 knockdown [19,43].…”

“…Sections were incubated with DAKO EnVision+-HRP secondary antibody (Agilent Technologies, Santa Clara, CA, USA; Cat# K4003) for 10 min, followed by BOND Polymer Refine Detection DAB chromogen (Leica, Cat# DS9800). Tissue slides were probed with the following antibodies: IGF2BP3 [ 38 ] (Cell Marque, Rocklin, CA, USA; Cat# 433R, EP286, 1:25) and PDL1 (Abcam, Cambridge, United Kingdom; Cat# ab228462, 1:100). Tissue cores were annotated via pathological identification (path ID) using tissue maps, and manually verified by an expert pathology review (authors SD and MN).…”

Insulin-like Growth Factor II mRNA-binding Protein 3 is a Highly Sensitive Marker for Intravascular Large B-cell Lymphoma

“…17 Notably, its expression has been detected in classic Hodgkin lymphoma and most high-grade non-Hodgkin B-cell lymphomas. [18][19][20][21] In our practice, we use IMP3 as a useful marker for these lymphomas, especially in small biopsy specimens with low numbers of tumor cells. Using a single institutional cohort, we performed immunohistochemistry (IHC) for IMP3 on skin biopsies and found IMP3 to be a highly sensitive marker for IVLBCL in skin biopsies.…”

“…Despite its absence in most normal adult tissues, 16 variable IMP3 expression is observed in human neoplasms 17 . Notably, its expression has been detected in classic Hodgkin lymphoma and most high-grade non-Hodgkin B-cell lymphomas 18–21 . In our practice, we use IMP3 as a useful marker for these lymphomas, especially in small biopsy specimens with low numbers of tumor cells.…”